Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells 4,813 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) CAO Patricia Carr sold 4,813 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the transaction, the chief accounting officer now directly owns 8,237 shares of the company's stock, valued at $1,189,587.54. The trade was a 36.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ traded up $2.36 during mid-day trading on Friday, reaching $138.81. 1,226,548 shares of the company were exchanged, compared to its average volume of 763,953. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market cap of $8.43 billion, a PE ratio of 19.55, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06. The company has a fifty day moving average of $127.85 and a 200 day moving average of $119.83.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Barclays restated an "overweight" rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. TD Cowen cut their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their price target for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Morgan Stanley reiterated an "overweight" rating and set a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $130.00 to $170.00 in a report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $189.40.

Remove Ads

Institutional Trading of Jazz Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. LSV Asset Management raised its position in Jazz Pharmaceuticals by 1.5% in the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after purchasing an additional 37,108 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after buying an additional 115,102 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after acquiring an additional 320,724 shares during the last quarter. Capital World Investors lifted its stake in shares of Jazz Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock valued at $236,860,000 after acquiring an additional 104,195 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after acquiring an additional 315,608 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.